Free Trial

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Up 428.1% in December

Fresenius SE & Co. KGaA logo with Medical background

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 63,900 shares, a growth of 428.1% from the December 15th total of 12,100 shares. Based on an average daily trading volume, of 124,300 shares, the days-to-cover ratio is presently 0.5 days.

Fresenius SE & Co. KGaA Price Performance

Shares of OTCMKTS:FSNUY traded down $0.12 on Monday, reaching $8.89. 85,939 shares of the company were exchanged, compared to its average volume of 127,662. The company has a current ratio of 1.36, a quick ratio of 1.05 and a debt-to-equity ratio of 0.57. Fresenius SE & Co. KGaA has a 1-year low of $6.57 and a 1-year high of $9.78. The company has a 50-day moving average of $8.87 and a 200-day moving average of $8.88. The firm has a market cap of $19.86 billion, a price-to-earnings ratio of 12.36 and a beta of 1.02.

Analyst Upgrades and Downgrades

Separately, Citigroup upgraded shares of Fresenius SE & Co. KGaA to a "strong-buy" rating in a research note on Friday, October 25th.

Check Out Our Latest Report on FSNUY

About Fresenius SE & Co. KGaA

(Get Free Report)

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fresenius SE & Co. KGaA Right Now?

Before you consider Fresenius SE & Co. KGaA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. KGaA wasn't on the list.

While Fresenius SE & Co. KGaA currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

While 2025 may not deliver massive returns, so MarketBeat analyst Chris Markoch shares his list of seven stocks primed for consistent performance.

Related Videos

3 Stocks Insiders Are Selling, But Analysts Still Love
NVIDIA Unveils Game-Changing Tech, But Stock Dips
The Future of Healthcare: 3 AI Stocks Leading the Way

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines